Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Top Page
Esperion
(NASDAQ:ESPR)
Rating:60Neutral
Price Target:
$2.00
▼(-28.32% Downside)
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective product adoption, supporting long-term business sustainability.
International Expansion
Growing international partnerships enhance market reach and revenue potential, strengthening Esperion's global market position.
Regulatory Recognition
Regulatory endorsement in Europe validates product efficacy and boosts credibility, potentially increasing adoption and sales.
Negative Factors
Financial Instability
Negative equity and high leverage pose risks to financial health, limiting flexibility and increasing vulnerability to economic shifts.
Cash Flow Challenges
Ongoing cash flow issues can hinder operational capabilities and growth investments, impacting long-term business viability.
Profitability Concerns
Sustained profitability challenges highlight operational inefficiencies, potentially affecting future growth and shareholder value.
Esperion (ESPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$562.53M
Dividend YieldN/A
Average Volume (3M)5.90M
Price to Earnings (P/E)―
Beta (1Y)2.72
Revenue Growth-3.48%
EPS Growth36.57%
CountryUS
Employees304
SectorHealthcare
Sector Strength51
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding201,622,820
10 Day Avg. Volume7,440,495
30 Day Avg. Volume5,899,123
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.06
Price to Sales (P/S)1.24
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue2.64
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda-28.74
Forecast
1Y Price Target
$7.13Price Target Upside155.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Esperion Business Overview & Revenue Model
Company DescriptionEsperion Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). The company operates primarily in the pharmaceutical sector, concentrating on cardiovascular diseases. Esperion's core products include bempedoic acid and its combination therapy with ezetimibe, aimed at providing effective solutions for individuals who are unable to achieve their cholesterol goals with traditional statin therapy.
How the Company Makes MoneyEsperion generates revenue primarily through the sale of its pharmaceutical products, particularly bempedoic acid, which is marketed under the brand name Nexletol. The company earns revenue by selling these products to healthcare providers and pharmacies, which in turn sell them to patients. Additionally, Esperion may receive royalties and milestone payments from partnerships and collaborations with larger pharmaceutical companies that have been established to enhance distribution and marketing efforts. Such partnerships can also facilitate access to broader markets and boost sales. Furthermore, the company may benefit from government and private health insurance reimbursements that cover the cost of its therapies, contributing significantly to its overall revenue.
Esperion Earnings Call Summary
Earnings Call Date:Aug 11, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call highlighted Esperion's robust financial performance with significant revenue growth and strategic achievements, such as achieving operating income for the first time and strong international partnerships. While there were some concerns about collaboration revenue and milestone payments, the positive aspects of the company's growth and strategic initiatives significantly outweigh the challenges.Q2-2025 Updates
Positive Updates
Record Revenue Growth
Esperion reported a 12% year-over-year increase in total revenue for Q2 2025, reaching $82.4 million. U.S. net product sales saw a 42% increase year-over-year to $40.3 million.
First Operating Income
Esperion achieved its first quarter of operating income from ongoing business, amounting to approximately $15 million, signaling a transition towards sustainable profitability by Q1 2026.
Significant Increase in Prescriptions
Esperion reported double-digit sequential growth in prescriptions, with a 10% increase in total retail prescription equivalents from Q1 2025.
Strong International Performance
Royalty revenue from Daiichi Sankyo Europe increased 30% from Q1 2025, and the company surpassed the 500,000 patient mark in Europe.
Successful Marketing Campaigns
The 'Can't take a statin? Make NEXLIZET happen' campaign drove significant brand awareness, with 650,000 visits to the consumer website and 600,000 click-throughs to the physician site.
Intellectual Property Settlements
Esperion reached settlement agreements with three generic manufacturers to delay the marketing of generic NEXLETOL in the U.S. until 2040.
Negative Updates
Collaboration Revenue Decline
Collaboration revenue decreased by 7% compared to the same period in 2024, primarily due to a settlement milestone in the prior year, although this was offset by a 105% increase when excluding the milestone.
Uncertainty in Milestone Payments
Concerns were raised regarding the timing and conditions of milestone payments from Otsuka Pharmaceuticals, though management expressed confidence in achieving the full amount.
Company Guidance
During Esperion's Second Quarter 2025 earnings call, the company reported strong financial performance, highlighted by a 42% year-over-year increase in U.S. net product revenue, reaching $40.3 million, and a total revenue growth of 12% year-over-year to $82.4 million. This period marked their first quarter of operating income from ongoing business, approximately $15 million, and a sequential quarterly revenue growth of 15%. Esperion emphasized the robust adoption of their products NEXLETOL and NEXLIZET, driven by effective marketing strategies and favorable reimbursement landscapes, which led to over 80% approval rates among targeted prescribers. The company also noted significant gains in digital engagement, with 38% of prescriptions prompted by digital-only interactions. Their international partnerships contributed to the revenue, with a 30% increase in royalty revenue from Daiichi Sankyo Europe. Looking ahead, Esperion is optimistic about transitioning to sustainable profitability by the first quarter of 2026 and anticipates continued growth fueled by both domestic and international market expansions.Esperion Financial Statement Overview
Summary
Esperion shows strong revenue growth but faces significant challenges with profitability and financial stability. The negative equity and high leverage are concerning, and cash flow remains negative despite some improvements.Income Statement
Esperion has shown significant revenue growth from 2023 to 2024, with a Revenue Growth Rate of 185.6%. However, the company is still facing challenges with profitability as indicated by the negative Net Profit Margin of -15.6% in 2024. The Gross Profit Margin improved to 79.3%, but the negative EBIT and EBITDA margins reflect ongoing operational challenges.45
Neutral
Balance Sheet
The balance sheet reveals a concerning negative Stockholders' Equity of -$388.7 million, indicating financial instability. The Debt-to-Equity Ratio is not calculable due to negative equity, highlighting high leverage. The Equity Ratio is also negative, suggesting that liabilities exceed assets, which poses a significant risk.30
Negative
Cash Flow
Esperion's cash flow situation is challenging, with a negative Free Cash Flow of -$23.97 million in 2024. The Operating Cash Flow to Net Income Ratio is negative, indicating cash flow issues relative to net losses. However, the company has managed to reduce its negative Free Cash Flow compared to previous years, showing some improvement.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 268.13M | 332.31M | 116.33M | 75.47M | 78.45M | 227.55M |
| Gross Profit | 173.06M | 263.71M | 73.07M | 48.51M | 64.23M | 225.16M |
| EBITDA | -24.59M | 7.57M | -150.11M | -176.35M | -222.14M | -120.33M |
| Net Income | -96.09M | -51.74M | -209.25M | -287.82M | -318.82M | -166.19M |
Balance Sheet | ||||||
| Total Assets | 347.08M | 343.82M | 205.80M | 247.94M | 381.59M | 353.26M |
| Cash, Cash Equivalents and Short-Term Investments | 86.06M | 144.76M | 82.25M | 124.78M | 208.89M | 304.96M |
| Total Debt | 146.45M | 591.21M | 540.95M | 260.95M | 260.20M | 185.41M |
| Total Liabilities | 780.59M | 732.54M | 660.79M | 571.72M | 578.53M | 449.39M |
| Stockholders Equity | -433.51M | -388.72M | -454.99M | -1.34B | -1.11B | -838.82M |
Cash Flow | ||||||
| Free Cash Flow | -124.49M | -23.97M | -135.49M | -174.83M | -263.81M | -98.55M |
| Operating Cash Flow | -124.33M | -23.65M | -135.49M | -174.83M | -263.81M | -85.18M |
| Investing Cash Flow | -167.00K | -317.00K | 42.50M | 8.10M | -50.48M | 21.36M |
| Financing Cash Flow | 21.25M | 86.48M | 50.46M | 32.61M | 268.22M | 201.72M |
Esperion Technical Analysis
Positive
2.79
Price Trends
1.77
Positive
1.37
Positive
1.67
Positive
Market Momentum
0.26
Negative
78.30
Negative
83.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ESPR, the sentiment is Positive. The current price of 2.79 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 1.77, and above the 200-day MA of 1.67, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 78.30 is Negative, neither overbought nor oversold. The STOCH value of 83.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ESPR.
Esperion Risk Analysis
Esperion disclosed 69 risk factors in its most recent earnings report. Esperion reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Esperion Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $439.08M | 3.36 | 30.24% | ― | -22.74% | ― | |
60 Neutral | $562.53M | ― | 23.44% | ― | -3.48% | 36.57% | |
56 Neutral | $590.35M | ― | 77.48% | ― | -24.38% | -94.72% | |
54 Neutral | $193.38M | ― | -57.22% | ― | -27.40% | -475.41% | |
52 Neutral | $201.42M | 85.74 | -8.02% | ― | -22.98% | -173.28% | |
51 Neutral | $8.02B | -0.39 | -43.38% | 2.20% | 22.34% | -2.13% | |
48 Neutral | $290.66M | ― | -76.41% | ― | 0.47% | -430.88% |
* Healthcare Sector Average
Performance Comparison
ESPR
Esperion
2.79
0.88
46.07%
EBS
Emergent Biosolutions
8.23
0.36
4.57%
IRWD
Ironwood Pharma
1.24
-3.33
-72.87%
LFCR
Lifecore Biomedical
7.52
2.34
45.17%
AQST
Aquestive Therapeutics
5.05
0.21
4.34%
DERM
Journey Medical Corp
7.35
2.19
42.44%
Esperion Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Esperion Expands Board with New Appointment
Positive
Jul 1, 2025
On July 1, 2025, Esperion announced the appointment of Craig Thompson, CEO of Cerevance, to its Board of Directors, expanding the board to eight members. Thompson’s extensive experience in biopharmaceutical leadership is expected to enhance Esperion’s strategic direction as it continues to innovate in cardiovascular and cardiometabolic drug development, potentially impacting its market position and stakeholder interests.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.